Who Owns Assertio Company?

Assertio Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Assertio Holdings, Inc.?

Understanding Assertio Holdings, Inc.'s ownership is key for stakeholders. The company, originally Depomed, Inc., became Assertio Holdings, Inc. in May 2020 after merging with Zyla Life Sciences.

Assertio Holdings, Inc. focuses on specialty pharmaceutical products, particularly in neurology and pain management. Its market cap as of August 14, 2025, is around $78.38 million.

Institutional investors hold a significant stake in Assertio Holdings, Inc. This structure influences its strategic decisions and market presence.

The company's product portfolio includes treatments aimed at improving patient outcomes. For instance, their work in pain management is a key area, and a deeper look at their market environment can be found in the Assertio PESTEL Analysis.

Assertio Holdings, Inc. traces its origins back to 1995 when it was established as Depomed, Inc. While the company's founding year is documented, specific details about its original founders, their professional backgrounds, and the initial equity distribution are not readily available in current public disclosures. Information regarding early investors, angel backers, or initial ownership agreements is also not detailed in recent financial filings.

Early Corporate Identity

The company commenced operations in 1995 under the name Depomed, Inc. This marked the initial phase of its corporate existence.

Founder Information Scarcity

Specific details concerning the full identities of the founders and their initial roles are not extensively documented in recent public filings.

Initial Investment Landscape

Information on early backers, angel investors, or friends and family who participated in the initial funding rounds is not a focus of current disclosures.

Early Ownership Agreements

Details regarding initial equity splits, vesting schedules, or buy-sell clauses from the company's inception are not publicly detailed.

Corporate Evolution Impact

Significant corporate changes, including rebranding and mergers, have shifted public information focus to current ownership structures.

Rebranding and Merger Context

The company rebranded to Assertio Therapeutics in 2018 and underwent a merger in 2020, influencing the availability of historical founding ownership data.

The company's journey from Depomed, Inc. to its current structure as Assertio Holdings, Inc. involved significant transformations, including a rebranding in 2018 and a merger in 2020. These events have led to a greater emphasis on current corporate governance and major institutional holdings in public disclosures, rather than the specifics of its initial founding ownership. Understanding the Growth Strategy of Assertio provides context for these structural changes.

Key Aspects of Early Ownership

While the company was founded in 1995 as Depomed, Inc., detailed information regarding its founders, their backgrounds, and the initial ownership structure is not readily available in current public records.

• Founding year: 1995
• Original company name: Depomed, Inc.
• Lack of detailed founder information in current disclosures.
• Absence of specific data on early investors and agreements.
• Focus of current disclosures on post-merger and rebranding ownership.

Assertio SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Assertio Holdings, Inc., formerly Depomed, Inc., has seen significant changes in its ownership structure since its 1997 IPO, with a notable transformation occurring through its May 2020 merger with Zyla Life Sciences. This merger led to the company's rebranding as Assertio Holdings, Inc., signaling a strategic shift in its business focus and product offerings.

The Assertio ownership landscape is dynamic, with institutional investors playing a substantial role. As of August 2025, these entities collectively held approximately 27.26% of the company's stock. This broad institutional backing includes significant positions held by firms such as Nantahala Capital Management, LLC, which saw a 4.388% change in its holding as of June 30, 2025, acquiring 8,810,073 shares. Other major institutional stakeholders include Vanguard Group Inc with 4,384,211 shares and Renaissance Technologies Llc with 2,822,137 shares. The active trading by these entities, with 19 institutions adding to their positions and 44 reducing them in Q1 2025, highlights a constantly evolving investor sentiment and contributes to the overall market perception of Assertio company stakeholders.

Key Institutional Holders of Assertio

Several prominent institutional investors maintain significant stakes in Assertio Holdings, Inc., influencing its market dynamics.

• Nantahala Capital Management, LLC
• Vanguard Group Inc
• Renaissance Technologies Llc
• BlackRock, Inc.
• Geode Capital Management, Llc

Beyond these major players, other significant institutional holders as of June 30, 2025, include BlackRock, Inc. (1,374,661 shares), Geode Capital Management, Llc (1,021,383 shares), CM Management, LLC (724,382 shares), Millennium Management Llc (694,525 shares), Aqr Capital Management Llc (450,902 shares), Morgan Stanley (438,492 shares), and Two Sigma Investments, Lp (435,370 shares). This diverse group of Assertio company stakeholders underscores the company's status as a publicly traded entity with broad investor interest. Understanding these Assertio Holdings ownership patterns is crucial for assessing the company's financial health and strategic direction, as detailed in analyses such as the Marketing Strategy of Assertio.

Assertio PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current Board of Directors for Assertio Holdings, Inc. is instrumental in guiding the company's strategic direction and governance. As of late 2024, the board includes Heather L. Mason as Board Chair, alongside CEO Brendan O'Grady. The board is further comprised of directors William T. McKee, Sravan K. Emany, Sigurd C. Kirk, Mark L. Reisenauer, and David Matthew Stark, with Peter Staple and Dr. Jeffrey Vacirca having retired in November 2024.

Assertio Holdings, Inc. operates under a typical one-share-one-vote system for its common stock, a standard for publicly traded entities, with no publicly disclosed dual-class shares or special voting rights. The board's composition reflects a blend of executive leadership, representation from significant institutional investors, and independent members, ensuring diverse perspectives in decision-making. While board membership has seen recent adjustments, there are no current indications of significant proxy contests or activist campaigns that have fundamentally altered the company's voting power structure.

Understanding Assertio's Ownership Structure

Assertio Holdings, Inc. is a publicly traded company, meaning its ownership is distributed among various shareholders. The company's structure allows for broad participation in its ownership, reflecting its status in the public markets.

• Assertio is a publicly traded company.
• Ownership is generally based on a one-share-one-vote principle.
• Institutional investors often hold significant stakes.
• The board composition reflects a mix of internal and external expertise.
• Understanding the Target Market of Assertio can provide context for its strategic direction.

Assertio Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, Assertio Holdings, Inc. has undergone significant strategic shifts impacting its ownership structure. Key developments include a major acquisition and divestitures, alongside leadership changes, all aimed at refining its market position and operational focus.

Institutional investors have shown a slight decrease in their holdings of Assertio Holdings, Inc. between October 2024 and March 2025, moving from 30.03% to 27.37%. This period also saw insider holdings remain relatively stable at approximately 2.5% as of March 2025. The company's strategic direction, as communicated in May 2025, emphasizes sustainable growth from its commercial pharmaceutical assets, with stated goals for 2025 including increased net sales, positive cash flow, and achieving EBITDA guidance.

Institutional Investor Activity

Between October 2024 and March 2025, institutional investors reduced their stake in Assertio Holdings, Inc. from 30.03% to 27.37%.